tirzepatide

GLP-1 drugs: clinical trends, safety, and market shifts

259 clusters · 928 sources · last updated about 6 hours ago

Latest: Medical experts warn of weight regain risks for GLP-1 users

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

Expanded therapeutic research and management of GLP-1 drugs

16 clusters · 102 sources · last updated 1 day ago

Latest: Semaglutide may reduce asthma attacks and impact weight maintenance

Medical research continues to expand the known therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. Beyond their primary uses for diabetes and obesity, these medications are being linked to

Brazil ANVISA expands product safety enforcement

32 clusters · 245 sources · last updated 5 days ago

Latest: Anvisa bans Paraguayan T36 weight-loss medication in Brazil

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

Eli Lilly retatrutide development and black market issues

9 clusters · 28 sources · last updated 8 days ago

Latest: Retatrutid research shows potential for obesity treatment

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

Illicit tirzepatide trade in Paraguay and Brazil

4 clusters · 24 sources · last updated 10 days ago

Latest: Brazilian police seize large quantities of tirzepatide

A legal and criminal crisis has emerged regarding the illicit trade of tirzepatide, the active ingredient in weight-loss medications, across the border regions of Paraguay and Brazil. In Paraguay, a criminal complaint w